Scientists expose deadly trick behind pancreatic cancer

Share this content:

In the early stages of pancreatic cancer, tumor cells establish an immunosuppressive environment that allows them to grow and divide freely, a discovery that could lead to more effective treatments for this aggressive disease.

Working with mouse models of pancreatic cancer, a team led by Dafna Bar-Sagi, PhD, of the New York University (NYU) School of Medicine in New York City, found that a mutation of the KRAS gene, which is present in 95% of all pancreatic cancers, triggers the expression of a protein known as GM-CSF. GM-CSF then directs accumulation of myeloid-derived suppressor cells in the area surrounding the tumor. These cells suppress the immune system's natural defense against growing tumor cells.

Blocking GM-CSF production in the cancer cells disrupted the accumulation of the suppressor cells and restored the immune system's tumor-killing response.

“Our study suggests a therapeutic strategy for harnessing the antitumor potential of the immune system,” commented Bar-Sagi in a statement issued by NYU Langone Medical Center/NYU School of Medicine to announce the group's results, which were published in the journal Cancer Cell (2012;21[6]:836-847).

Because the vast majority of human pancreatic cancer samples tested by the investigators expressed the GM-CSF protein prominently, Bar-Sagi expects that the findings will be applicable to a significant proportion of human pancreatic cancer cases and is hopeful that the new information will eventually lead to new drug therapies that block the production or function of the GM-CSF protein. The research may also have implications for colon, lung, and other cancers in which KRAS mutations are prevalent.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs